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Membranous nephropathy is a major cause of nephrotic
syndrome in adults where podocyte injuries were found to
mediate the development of proteinuria. Triptolide, a major
active component of Tripterygium wilfordii Hook F, has potent
immunosuppressive, anti-inflammatory and antiproteinuric
effects. To study its antiproteinuric properties, we established
an experimental rat model of passive Heymann nephritis and
a C5b-9 injury model of podocytes in vitro. Treatment or
pretreatment with triptolide markedly reduced established
proteinuria as well as the titer of circulating rat anti-rabbit
IgG antibodies in these nephritic rats, accompanied by a
reduction in glomerular C5b-9 deposits. Expression of
desmin, a marker of podocyte injury, diminished after
triptolide treatment, whereas quantitative analysis of mean
foot process width showed that effacement of foot processes
was substantially reversed. In in vitro studies we found that
triptolide deactivated NADPH oxidase, suppressed reactive
oxygen species generation and p38 mitogen-activated
protein kinase, and restored RhoA signaling activity.
Triptolide did not interfere with the formation of C5b-9
on the membrane of podocytes. Thus, triptolide reduces
established heavy proteinuria and podocyte injuries in rats
with passive Heymann nephritis, and protects podocytes
from C5b-9-mediated injury.
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Immune-mediated podocyte injuries are crucial in the
development of proteinuria in many kinds of glomerulo-
nephritis, including membranous nephropathy. Membranous
nephropathy is a major cause of nephrotic syndrome in
adults. It accounts for 10% of primary glomerulonephritis
in China and approximately 30% in Western countries.1,2 It is
characterized by subepithelial immune deposits, podocyte
foot process effacement and expansion of the glomerular
basement membrane (GBM).3 Complement activation
and C5b-9 formation triggered by immune complex have
major roles in the development of tissue damage, whereas
podocytes are important target cells during this process.4,5
Although some patients with membranous nephropathy
remit spontaneously, therapeutic strategies for those with
persistent severe proteinuria and progressive loss of renal
function are toxic and not uniformly effective. Approximately
one-third of patients may develop progressive renal disease.6
Triptolide, an active component of the medicinal plant
Tripterygium wilfordii Hook F (TWHF),7 has potent immuno-
suppressive and anti-inflammatory therapeutic effects.
Triptolide has been shown to inhibit the proliferation of
lymphocytes and induces apoptosis of lymphocytes and
dendritic cells.8,9 Triptolide is also a potent inhibitor of
NF-kappa B and NF AT-mediated transcription.10 These
characteristics of triptolide helped to partially explain the
therapeutic effects of TWHF extracts in autoimmune diseases.
In addition to the above properties, extracts of TWHF could
alleviate glomerular albumin permeability induced by various
stimuli such as protamine, tumor necrosis factor (TNF)-a and
the serum from patients with focal segmental glomerular
sclerosis in vitro,11 which implicated an intriguing possibility
that TWHF might protect the glomerular filtration barrier.
Zheng et al,12 reported that triptolide ameliorated puromycin
aminonucleoside (PAN)-mediated podocyte injuries in vivo
and in vitro, suggesting that beneficial therapeutic effects of
triptolide on proteinuria might be attributed to a protective
effect on podocytes.
According to the pathological process of membranous
nephropathy, an effective therapy should have the following
two effects, including the immunosuppression to prevent
antibody production and protection on podocyte from injury
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triggered by complement activation and C5b-9 formation.
These two therapeutic effects will help to reduce proteinuia
and block the progression of kidney disease. Immuno-
suppressive effect and direct podocyte protection of triptolide
will result in potential treatment of membranous nephro-
pathy. In this research, passive Heymann nephritis (PHN),
an animal model of membranous nephropathy was induced
in rats, which were then administrated triptolide orally to
determine whether triptolide could reduce the protein-
uria and improve podocyte injuries in this immune-mediated
podocyte injury. Furthermore, we use an in vitro assem-
bled functional terminal complement complex C5b-9 based
on purified complement protein to explore the thera-
peutic mechanism of triptolide on C5b-9-induced podocyte
damage.
RESULTS
Effect of triptolide on proteinuria
Present data showed that triptolide effectively reduced
urinary protein/creatinine ratio in PHN rats (Figure 1). Rats
with PHN developed heavy proteinuria and the ratio of
urinary protein to creatinine was 29.3±3.8. After treatment
with triptolide, the ratio was significantly reduced on day 7
(12.3±1.4 vs 22.5±2.9, Po0.01), on day 14 (5.5±0.7 vs
15.4±1.9, Po0.01), on day 21 (2.1±0.3 vs 9.8±1.2,
Po0.01) and on day 28 (0.9±0.2 vs 5.3±0.7, Po0.01).
Pretreatment with triptolide also significantly reduced the
urinary protein/creatinine ratio in PHN rats. However, there
was no significant difference in the ratio between the rats
with triptolide pretreatment and those with treatment.
Consistent with the marked decrease of proteinuria,
plasma albumin level was increased after treatment with
triptolide (Figure 2). Level of plasma albumin in PHN
rats was significantly lower than that of healthy rats before
treatment (Po0.01). After treatment with triptolide for
7 days, plasma albumin level of PHN rats was distinctly
increased. On day 14, the therapeutic effect on plasma
albumin was still obvious.
Effect of triptolide on glomerular histological changes
Rats with PHN showed subepithelial immune deposit
formation on day 14 (Figure 3). After treatment with
triptolide, subepithelial immune deposits were not signi-
ficantly decreased as compared with the untreated PHN rats
at the same time. Transmission electron microscopic obser-
vation indicated that there was no obvious difference in the
amount of subepithelial electron dense deposits between
triptolide-treated rats and PHN control rats (Figure 4).
Change of rat IgG in serum and glomeruli after treatment
with triptolide
The titre of circulating rat anti-rabbit IgG antibodies in PHN
rats was 100±5 before treatment (10 days after the injection
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Figure 1 | Triptolide significantly reduced urinary protein/
creatinine ratio in rats with passive Heymann nephritis. After
treatment with triptolide for 7, 14, 21 and 28 days, the urinary
protein/creatinine ratio in PHN rats was significantly reduced.
There was no significant difference in the ratio between the rats
with triptolide pretreatment and those with treatment. **Po0.01
vs PHN. PHN, passive Heymann nephritis.
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Figure 2 |Change of plasma albumin in PHN rats after
treatment with triptolide. After treatment with triptolide for
7 days, plasma albumin level of PHN rats was distinctly increased.
On day 14, the therapeutic effect on plasma albumin was still
obvious. DP40.05 vs PHN. *Po0.05, **Po0.01 vs PHN.
Figure 3 | Effect of triptolide on light microscopic appearance
of subepithelial immune depositions of PHN rats on day 28
(PASM 400). (a) PHN rats on day 28. (b) PHN rats treated with
triptolide on day 28. Subepithelial immune depositions are shown
with arrows. After treatment with triptolide, subepithelial immune
deposition was not significantly decreased.
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of anti-Fx1A rabbit serum). The titre increased to a peak of
1:(300±20) on day 14 (24 days after the rabbit serum
injection), then decreased gradually. After treatment with
triptolide, the titre of circulating rat anti-rabbit IgG anti-
bodies in PHN rats was markedly lower than that in PHN
rats without treatment on day 7 (1:(120±10) vs 1:(200±15),
Po0.01), day 14 (1:(160±10) vs 1:(300±20), Po0.01), day
21(1:(140±15) vs 1:(200±15), Po0.01), and day 28
(1:(140±10) vs 1:(200±20), Po0.01; Figure 5). After treat-
ment with FK506, circulating rat anti-rabbit IgG antibodies
in PHN rats was also effectively inhibited, the titre on day 7
was 1:(100±10) and on day 14 until day 28 was 1:(120±10).
Immunofluorescence staining showed that deposition
of rat IgG in glomeruli of PHN rats was in granular and
disperse pattern along the capillary wall. Compared with
PHN rats without treatment, fluorescence intensity of rat
IgG deposition decreased after treatment with triptolide for
7 and 14 days. However, on days 21 and 28, the difference in
fluorescence intensity was not highly significant between
PHN rats with or without triptolide treatment (Figure 6).
Change in C5b-9 deposition in the glomeruli after treatment
with triptolide
Immunofluorescence staining showed that C5b-9 deposits in
PHN rats had a similar pattern with IgG deposition.
Compared with PHN rats without treatment, the fluores-
cence intensity of C5b-9 deposition decreased after treatment
with triptolide for 7 and 14 days. However, on days 21 and
28 there was no significant difference on the fluorescence
intensity between PHN rats with or without triptolide
treatment (Figure 7).
Triptolide promoted the recovery of podocyte injuries
Desmin was used in this research as a biomarker to indicate
podocyte injuries. Immunohistochemical studies showed that
desmin expression was upregulated in PHN rats (Figure 8).
In the normal kidney, anti-desmin antibody reacted weakly
with the mesangial cells, whereas staining in the podocytes
was negative. In PHN rats, conspicuously enhanced staining
for desmin was noted in the podocytes, whereas triptolide
treatment resulted in a decrease in desmin expression.
Although desmin expression was decreased gradually in the
vehicle-treated group, the desmin expression was significantly
reduced in the triptolide treatment group on day 14, 21,
and 28.
Results of observation with transmission electron micro-
scopy indicated that podocyte injuries in PHN could be
reversed after treatment with triptolide (Figure 9). On day 7,
foot process effacement and disappearance of slit diaphragms
were observed in PHN rats under the electron microscope.
On days 14, 21, and 28, the injuries of podocytes, including
extensive foot process effacement, were becoming more
severe. After treatment with triptolide, the amelioration of
podocyte injuries was remarkable. Foot process effacement
was improved and reversed. Most foot processes in the
triptolide-treated PHN rats were restored to a normal shape
on day 28. The secondary foot process of podocytes was also
restored to normal shape and structure.
Quantitative analysis of mean foot process width showed
that triptolide effectively improved the reverse of foot
process effacement (Figure 10). Compared with PHN rats, foot
process width in the triptolide-treated group was significantly
decreased on day 7 (810±132nm vs1124±199nm, Po0.01),
day 14 (698±116nm vs1228±170nm, Po0.01), day 21 (584±
86nm vs 827±117nm, Po0.01) and day 28 (508±116nm vs
732±160nm Po0.01). After treatment with triptolide for
28 days, the foot process width of podocytes was restored closely
to the normal range.
Triptolide improved the expression and distribution of
nephrin
In PHN rats, decreased expression and granular distribution
of nephrin were obvious on day 7. Nephrin expression began
to increase but a dot-like pattern still remained on day 14.
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Figure 4 |Change of subepithelial immune deposition in
glomeruli of PHN rats after the treatment with triptolide for
28 days (EM). (a) PHN rats on day 28. (b) PHN rats treated with
triptolide on day 28. Immune deposits in the subepithelial layer
are indicated by asterisks. (c) Semiquantification of immune
deposits.
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Figure 5 | Triptolide effectively reduced circulating rat anti-
rabbit IgG antibodies (titer, reciprocal of the dilution) in rats
with passive Heymann nephritis. Po0.01 vs PHN.
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The expression and distribution of nephrin recovered gradually;
however, the discontinuous pattern was still observed along
the glomerular basement membrane on days 21 and 28.
Triptolide treatment significantly improved the expression
and distribution of nephrin. The expression of nephrin was
markedly increased after treatment with triptolide for 7 days,
and the distribution pattern began to recover. The increase of
expression and linear distribution of nephrin became more
obvious on days 14 and 21. On day 28, both the expression
and distribution of nephrin were almost completely reco-
vered. Quantification by western blot also confirmed that
triptolide remarkably improved the expression of nephrin in
PHN rats (Figure 11).
Adverse effect of treatment with triptolide
Triptolide has side effects including gastrointestinal tract
disturbances, leucopenia, and liver toxicities. After the
induction of PHN, rats had a normal appetite and good
physical condition except for proteinuria. To monitor the
adverse effect of treatment with triptolide, the serum alanine
transaminase (ALT), aspartate transaminase (AST), serum
creatinine (Scr) and white blood cell count were examined.
Oral administration of triptolide with doses used in this
research had no obvious adverse effects on rats. After
treatment for 28 days, ALT in the PHN groups treated
with triptolide and untreated was 34.6±11.0U/l and 32.4±
5.41U/l, respectively. AST in the PHN groups treated with
triptolide and untreated was 91.8±18.4 U/l and 83.6±
12.5 U/l, respectively. White blood cell count in the
PHN groups treated with triptolide and untreated was
5.0±0.9 109/l and 4.9±0.7 109/l, respectively. There was
no difference between the two groups treated with or without
triptolide. Although serum creatinine was a little increased in
the triptolide-treated group (72.6±15.8 mmol/l) compared
with untreated PHN rats (47.6±13.6 mmol/l), the difference
between two groups was not significant (P40.05).
The effect of triptolide on C5b-9 assembly in vitro
We further used the in vitro assembled functional terminal
complement complex C5b-9, based on purified complement
protein to verify the direct effect of triptolide on C5b-9-
induced podocyte injury. In these experiments, the C5b6
complex was used in limiting dilutions, while maintaining
fixed concentrations of C7, C8 and C9 (10 mg/ml) to assemble
C5b-9. The sublytic concentration of C5b-9 on podocytes
was determined by the lactate dehydrogenase release assay.
Dilutions of C5b6 o0.8 mg/ml did not increase the
concentration of released lactate dehydrogenase as compared
with unstimulated podocytes. However, when the concentra-
tion of C5b640.8 mg/ml, significantly higher levels of lactate
dehydrogenase release (410%) were noted (Figure 12A).
These results showed that assembly of functional C5b-9
with the initial 0.8 mg/ml did not have a significant effect
on podocyte membrane integrity. As a result, a C5b6 concen-
tration of 0.8 mg/ml was used for subsequent experiments.
The laser scan confocal microscopy assay using human
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Figure 6 | The effect of triptolide on IgG deposition in
glomeruli of PHN rats (magnification,  400). (a–d) PHN rats on
day 7, 14, 21 and 28, respectively; (e–h) PHN rats were treated with
triptolide for 7, 14, 21 and 28 days, respectively; (i) quantification of
the intensity of fluorescent staining for rat IgG in PHN rats after
treatment with triptolide. **Po0.01 vs PHN.
Kidney International (2010) 77, 974–988 977
Z-H Chen et al.: Triptolide reduces proteinuria and protects against podocyte injury o r ig ina l a r t i c l e
C5b-9-specific mAb aE11 showed fine granular deposits of
C5b-9 on the membrane of podocytes (Figure 12C). This
result was consistent with the result obtained by flow
cytometry analysis. The mean fluorescence intensity of cells
stained with C5b-9 antibody was apparently higher than
the negative control (Figure 12B). Furthermore, the sublytic
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Figure 7 |The effect of triptolide on C5b-9 deposition in
glomeruli of PHN rats (magnification,  400). (a–d) PHN rats on
day 7, 14, 21, and 28 days, respectively; (e–h) PHN rats were
treated with triptolide for 7, 14, 21, and 28 days, respectively;
(i) Quantification of the intensity of fluorescent staining for C5b-9
in PHN rats after treatment with triptolide for 7, 14, 21, and
28 days. **Po0.01 vs PHN.
Figure 8 | The effect of triptolide on the expression of desmin,
a biomarker of podocyte injuries. (a–d) represented
the desmin expression in podocytes of PHN rats, which were
treated with vehicle for 7, 14, 21, and 28 days, respectively.
(e–h) showed that desmin expression was ameliorated after
treatment with triptolide for 7, 14, 21, and 28 days, respectively.
(i) Expression of desmin was not observed in podocytes
of control rats.
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concentration of C5b-9 caused podocyte cytoskeleton
reorganization in a time-dependent manner. Treatment of
podocytes with C5b-9 for 30min and 1 h only caused F-actin
disorderliness and rarefaction of filaments. Treatment of
podocytes with C5b-9 for 3 h resulted in dramatic loss of
transcytoplasmic actin stress fiber (Figure 12D). However,
disrupted actin stress fiber was partially reversed after C5b-9
treatment for 6 h.
To investigate whether the protective effect of triptolide on
podocyte injury was related with the inhibition of C5b-9
assembly, we treated podocytes with triptolide for 30min
before exposure to purified complement protein and detected
C5b-9 deposition on the membrane of podocytes by confocal
microscopy and flow cytometry. Neither the distribution
nor the intensity of the C5b-9 complex had a significant
difference between the C5b-9 group and the triptolide
pretreated group (Figure 13b–d). Lactate dehydrogenase
release assay showed that the C5b-9-mediated cytolysis was
not affected in the presence of triptolide (Figure 13a).
The effect of triptolide on cellular reactive oxygen species
(ROS) production induced by C5b-9
C5b-9 increased ROS production within 30min by nearly
4-fold compared with control in podocytes. This effect was
maintained for 90min (Figure 14A). To determine whether
plasma membrane NADPH oxidase, the mitochondrial
pathway, or both were responsible for intracellular ROS
generation, we exposed podocytes to C5b-9 in the presence of
various chemical inhibitors of these ROS synthesis pathways.
Myxothiazol inhibits the mitochondrial respiratory chain at
cytochrome b-c1, and TTFA is an inhibitor of mitochondria
electron transport chain complex II. Mitochondrial electron
chain blocker myxothiazol and TTFA had no significant effect
on the increase of intracellular ROS induced by C5b-9,
However, ROS production and F-actin disruption induced by
C5b-9 were blocked by the NADPH oxidase inhibitor
apocynin and DPI in podocytes (Figure 14B and D).
Pretreatment of podocytes with triptolide (10 ng/ml)
before C5b-9 exposure led to a significant reduction in the
cellular ROS level (Figure 14B). However, when podocytes
were treated with triptolide (10 ng/ml) after C5b-9 had been
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Figure 9 | Triptolide restored the foot process effacement in
PHN rats. (a–d) PHN rats on day 7, 14, 21, and 28, respectively.
(e–h) PHN rats were treated with triptolide for 7, 14, 21, and 28
days, respectively. Subepithelial electron-dense deposits are
denoted by asterisks. Slit diaphragm is denoted by arrows. After
treatment with triptolide, foot process effacement was improved
and reversed. Most foot processes in the triptolide-treated PHN
rats were restored to normal shape on day 28 (h).
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Figure 10 |Triptolide effectively reversed foot process effacement.
DPo0.01 vs controls. **Po0.01 vs PHN.
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assembled for 30min, it was observed that triptolide had no
significant inhibitory effect on C5b-9-induced ROS produc-
tion (Figure 14C).
NADPH oxidase is composed of several subunits, includ-
ing the p47phox which coalesce at the plasma membrane to
form the active enzyme complex. Immunostaining confirmed
the presence of the subunit p47phox in podocytes and showed
its translocation to the plasma membrane after C5b-9
assembly. Triptolide showed inhibition of p47phox transloca-
tion when treated with podocytes before but not after C5b-9
assembly for 30min (Figure 14E).
Triptolide inhibited C5b-9-induced p38 MAPK activation
To characterize the intracellular signaling pathway associated
with the protective effects of triptolide in podocytes, we
stimulated podocytes with C5b-9 or C5b-9 plus triptolide
for various time intervals and analyzed phosphorylation of
mitogen-activated protein kinases (MAPK). The family of
MAPK, including p38, extracellular signal-regulated kinase
(ERK) and c-Jun N-terminal kinase, is implicated in podocyte
injury. C5b-9 stimulated a strong increase in phosphorylated
p38 in podocytes after a 1 h incubation (Figure 15A). In
contrast, C5b-9 treatment had no significant effect on
phospho-ERK1/2 and phospho-c-Jun MAPK levels. The total
unphosphorylated p38, ERK, and c-Jun levels were not affected.
These results suggested that the activation of p38 MAPK
pathway was associated with podocyte injury induced by
C5b-9. Treatment of triptolide (10 ng/ml) before or after C5b-9
assembly for 30min effectively suppressed C5b-9-induced
phosphorylation of p38 MAPK (Figure 15B) in podocytes.
Triptolide did not affect basal phosphorylation of p38 MAPK.
The effect of triptolide on p38 MAPK activity was also
examined in PHN rats. It was found that phosphorylated p38
MAPK in the glomeruli of PHN rats was markedly decreased on
day 7 and day 14 after treatment with triptolide (Figure 15D).
Activations of p38 MAPK are required for C5b-9-induced
actin reorganization in podocytes
Next, we wished to determine whether increased p38 MAPK
activity was required for induction of cytoskeleton disruption
by sublytic C5b-9. Western blots showed that p38 inhibitor
SB-203580 (5 mmol/l) significantly suppressed C5b9-induced
phosphorylation of p38 MAPK, and effectively abrogated
C5b-9-induced cytoskeleton disarrangement (Figure 15c3).
The ERK inhibitor U0126 as well as JNK inhibitor SP600125
did not abolish C5b-9-induced cytoskeleton disruption (data
not shown).
Triptolide restored the activity of RhoA in podocytes
RhoA has been suggested to have an important role in cyto-
skeleton reorganization. To investigate whether RhoA-signaling
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Figure 11 | Triptolide significantly improved the nephrin
expression and distribution on podocytes of PHN rats
(magnification,  400). (a–d) PHN rats on day 7, 14, 21, and 28,
respectively; (e) Continuous and linear expression of nephrin in
normal control; (f–i) PHN rats were treated with triptolide for 7, 14,
21, and 28 days, respectively. ( j) Quantification of nephrin
expression by western blot in PHN rats after treatment with
triptolide. *Po0.05, **Po0.01 vs PHN, DPo0.01 vs normal control.
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pathways are involved in the effect of triptolide on podocytes,
we performed RhoA activation assay. As shown in Figure 16A
and B, C5b-9 treatment induced strong decline in RhoA
activity at 20B30min. When cells were pretreated with
triptolide before C5b-9 exposure, RhoA activity was partially
maintained. Total protein level of RhoA was not affected by
C5b-9 and triptolide treatment during the time of the test.
However, the increase of RhoA activation was markedly inhi-
bited by the specific RhoA inhibitor, C3 exoenzyme (1mg/ml).
Immunofluorescence staining was consistent with the result
fromwestern blotting, showing that inhibition of RhoA activity
by C3 exoenzyme abolished the protective effect of triptolide
on C5b-9-induced F-actin dissociation (Figure 16b3). These
results strongly suggested that restoration of RhoA activity
mediated the protective effect of triptolide.
DISCUSSION
Membranous nephropathy is one of common causes of nephritic
syndrome. Central pathogenesis of membranous nephro-
pathy is in situ formation of subepithelial immune deposits
that produce glomerular injury by damaging and/or activating
podocytes through complement-dependent processes.13–16
PHN, a classical rat model of human membranous
nephropathy, was induced by injection into rats of rabbit
antiserum against FxIA complex of the proximal convoluted
tubule. As glomerular podocytes shared some antigenic
determinants with the FxIA complex of the proximal
convoluted tubule, rabbit antibody rapidly combine with
glomerular antigen on podocytes and formed an in situ
immune complex in the subepithelial layer of the GBM.
Immune complexes can activate the complement system and
result in the assembly of C5b-9 on the cell membrane.
Sublytic C5b-9 could activate podocytes and induce the
production of ROS and proteases by podocytes. ROS then
initiated lipid peroxidation and subsequent degradation of
GBM. In addition, C5b-9 formation led to cytoskeletal
changes of podocytes with subsequent dissociation of
nephrin from the actin cytoskeleton, resulting in foot process
effacement and heavy proteinuria.17–19 In this pathological
process, the immune reaction was the initiation factor and
podocyte injuries were the crucial events in the development
of severe proteinuria.19,20 Therefore, suppressing immune
reaction and reducing podocyte injury become important
targets in the treatment of patients with membranous
nephropathy. This study showed that triptolide effectively
inhibited immune response and antibody production in
PHN rats, as well as reduced podocyte injury in vitro and
in vivo.
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Figure 14 |Roles of the ROS generation in the protective effect of triptolide. (A) C5b-9-induced cellular ROS generation in a
time-dependent manner. (B) ROS generation was examined in the presence of triptolide (10 ng/ml), NADPH oxidase inhibitors apocynin
(50mmol/l) and DPI (10 mmol/l), mitochondrial electron chain blocker TTFA (10 mmol/l) and myxothiazol (3 mmol/l). Podocytes were
incubated for 30 min with the above-mentioned inhibitors before stimulation with C5b-9 for 30 min. (C) Triptolide has no significant
inhibiting effect on C5b-9-induced ROS generation when podocytes were treated with triptolide after C5b-9 has been assembled for 30 min.
(D) (d1) Normal control. F-actin disruption induced by C5b-9 prevented by triptolide (d2), NADPH oxidase inhibitor Apo (d3), and DPI (d4),
but not mitochondrial electron chain blocker TTFA (d5) and myxothiazol (d6). (E) Immunostaining for the p47phox subunits of NADPH
oxidase showed triptolide inhibited p47phox migration to the cellular plasma after C5b-9 treatment. (e1) Untreated podocytes; (e2) C5b-9
treated-podocytes for 30 min; (e3): podocytes were preincubated for 30 min with triptolide (10 ng/ml) before C5b-9 exposure. All above
results presented are representative of three independent experiments. Values are expressed as mean±s.d., *Po0.05, **Po0.01 vs normal
control podocytes; ##Po0.01 vs C5b-9-treated podocytes.
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There is mounting evidence showing that triptolide has
strong immunosuppressive and anti-inflammatory activities.
Triptolide can not only inhibit the proliferation of lympho-
cytes, but also inhibit the production of many cytokines and
inflammatory mediators.8,21 In this research, triptolide was
given after severe proteinuria appeared in the autologous
phase. Development of PHN included the heterologous and
autologous phase. During the heterologous phase, injections
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Figure 15 |Roles of p38 MAPK-signaling pathways in the protective effect of triptolide. (A) Time course of C5b9 on p38 MAPK
activation. (B) Triptolide diminished p38 MAPK activation in C5b-9-treated podocytes. (C) p38 MAPK activation are required for C5b9-
induced actin reorganization in podocytes. (c1) Untreated podocytes; (c2) C5b-9 treated podocytes for 3 h; (c3): podocytes were
preincubated for 30 min with 5mmol/l SB-203580 before C5b-9 exposure. All above results presented are representative of three independent
experiments. Values are expressed as mean±s.d., **Po0.01 vs time point 0 h. (D) Western blotting for phosphorylated p38 MAPK in
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Figure 16 |Role of the RhoA-signaling pathway in the protective effect of triptolide. (A) Time course of RhoA activity inhibited by
C5b-9 in podocytes. Triptolide restored RhoA activity in C5b-9-treated podocytes, and RhoA inhibitor C3 exoenzyme abolished the effect of
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of heteroantibody specific for glomerular antigens led to
accumulation in the glomeruli. After 3–6 days the deposited
antibody might induce transient proteinuria. In the following
3–4 days, the recipient rats usually developed an immune
response to the heterologous immunoglobulin. The resulting
autologous antibody bound to the heteroantibody, which was
still present in the glomeruli, thereby inciting a new phase
of nephritis. The autologous phase was typically more
pronounced and persistent than the heterologous phase.22,23
Therefore, we started treatment with triptolide in PHN rats
10 days after anti-Fx1A antiserum injection when proteinuria
was fully established.
After treatment with triptolide, the titre of circulating
rat anti-rabbit IgG antibodies in PHN rats was markedly
inhibited. FK506, an immunosuppressive drug, could also
effectively inhibit the circulating anti-rabbit IgG antibodies in
PHN rats. The inhibition pattern was similar with triptolide
although the inhibition effect was stronger than that of
triptolide. These results indicated that triptolide decreased
the production of circulating IgG in PHN rats through
its immunosuppressive effect.
Although the glomerular deposition of IgG and C5b-9 was
reduced by treatment with triptolide at the beginning of the
treatment, the decrease of C5b-9 deposition is not parallel to
the reduction in proteinuria. On days 21 and 28, there was no
difference on the fluorescence intensity of C5b-9 between
PHN rats with or without triptolide whereas proteinuria
was markedly decreased in the group with tripolide
treatment. Electron microscopic observation indicated that
triptolide treatment could not obviously reduce the sub-
epithelial immune deposits. Therefore, the effect of triptolide
on reducing urinary protein could not be attributed to its
immunosuppressive activity because immune-mediated
injury happened much early in PHN rats. It was reported
that rat C3 deposition became clearly positive on day 2 and
significant podocyte injuries could be detected on day 7.23,24
In this research, triptolide treatment started 10 days after the
injection of rabbit anti-Fx1A antibodies. Local therapeutic
effect of triptolide on podocytes might be more important.
Pretreatment with triptolide also significantly reduced the
ratio of urinary protein to creatinine in PHN rats. However,
there was no difference on reducing proteinuria between
the triptolide treatment group and pretreatment group. In
addition, there was no significant difference in the immune
deposits including IgG, C3 and C5b9 between the triptolide
treatment group and pretreatment (data not shown). These
results indicated that non-immune effect of triptolide also
has important roles in reducing urinary protein.
The direct protective effect of triptolide on podocyte
injury has been confirmed by our previous studies in rats
with PAN-induced nephrosis.12 Injection of PAN in rat
produces severe proteinuria as a result of PAN-injured
podocytes. It was shown that pretreatment and treatment
with triptolide effectively reduced the proteinuria in rats with
PAN-induced nephrosis. The antiproteinuric effect was
associated with improvement in the foot process effacement,
a decrease in the podocyte injury marker desmin as well as
the restoration of nephrin and podocin expression and
distribution. In this research, pretreatment with triptolide
could significantly reduce the urinary protein in PHN. The
difference between the triptolide pretreatment and treatment
was not significant as in the PAN-induced nephrosis. Similar
observation on immune-mediated model and non-immune
mediated model suggested that triptolide has direct thera-
peutic effects on local podocyte injuries in PHN rats.
It was reported that calcineurin inhibitors reduced
proteinuria at the cost of a significantly decreased GFR.
In our previous work, we confirmed that triptolide had no
effect on GFR levels at the administered dose, which further
proved its independent action of reducing proteinuria.12
Taken together, we assumed that triptolide may have a
direct protective effect on podocyte injury in addition to
immunosuppression in this model.
An in vitro study further proved that triptolide could
protect podocyte from PAN-induced cytoskeleton disruption,
abnormalities in nephrin and podocin expression through
inhibition of ROS generation and the subsequent p38 MAPK
pathway, as well as restoration of RhoA activity. In PHN rats
we found that signs of podocyte injury were recovered after
triptolide treatment. Expression of desmin diminished after
treatment with triptolide, and quantitative analysis of the
mean foot process width showed that effacement of foot
processes was substantially reversed. Furthermore, triptolide
effectively restored the abnormalities of nephrin expression
and distribution. These results showed that podocyte injuries
in PHN could be reversed after treatment with triptolide.
To explore the underlying mechanism of triptolide action,
an in vitro model of C5b-9-induced podocyte injury was used
in this study. C5b-9 is crucial in the development of podocyte
injuries in membranous nephropathy. C5b-9 in sublytic
quantities stimulates podocytes to produce proteases,
oxidants, prostanoids, extracellular matrix and cytokines.
C5b-9 also causes alterations of the cytoskeleton that lead to
abnormal distribution of the slit diaphragm protein. These
events result in disruption of the functional integrity of the
glomerular basement membrane and the protein filtration
barrier of podocytes with subsequent development of
massive proteinuria.20 We assembled functional C5b-9 on
the membranes of podocytes in vitro based on purified
complement protein and observed that C5b-9 in sublytic
concentration caused disruption of F-actin cytoskeleton in
podocytes in vitro. Actin filament is a major constituent of
foot processes, and depolymerization of actin filaments leads
to foot process effacement.
There is accumulating evidence showing that complement
attack on various cells can induce generation of ROS.25–27
Oxidative stress induced by excess production of ROS has
been implicated in pathological processes of membranous
nephropathy. In support of a pathogenic role of oxidant
stress in membranous nephropathy, studies that have used
antioxidants and oxygen radical scavengers have shown
beneficial effects in the Heymann nephritis models,28,29 and
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also in a pilot study of human membranous nephropathy.30
Our study showed that sublytic C5b-9-induced ROS genera-
tion in podocytes was markedly increased within 30min and
this effect was maintained for 90min. And the present results
suggested that NADPH oxidase, rather than mitochondria,
were the primary source of superoxide production during the
C5b-9 attack. NADPH oxidase is a multicomponent enzyme
comprising a plasma membrane-bound subunit, gp91; a
membrane-associated flavocytochrome, cytochrome b558;
and at least three cytosolic subunits, p47phox p67phox and
the small G protein Rac2.31 During activation, the p47phox
component is phosphorylated and migrates to the plasma
membrane, where it associates with the other subunits to
form the active enzyme complex. Triptolide had been found
to inhibit PAN-induced cellular ROS in podocytes. In this
study, we found pretreatment podoyctes with tripolide lead
to inhibition of p47phox translocation and blocked the
production of ROS induced by C5b-9. However, it was
observed that triptolide had no significant inhibitory effect
on C5b-9-induced ROS generation when podocytes were
treated with triptolide after C5b-9 has been assembled for
30min. It may be due to the time point of tripotolide adding
to the culture system. NADPH oxidase activity is transient
with many stimuli.32 Furthermore, Alder25 showed in
mesangial cell that production of H202 after stimulation
with membrane attack complex continued to increase during
60min of incubation, whereas production of O2
 after
stimulation with membrane attack complex increased during
the first 20min of incubation, but then plateaued. The study
of Ren33 showed that triptolide effectively scavenged super-
oxide anion radical (O2
–), but not hydroxyl radical (OH–) as
detected by electron spin resonance and spin trapping. In rats
with Heymann nephritis, the fact that triptolide reverses
previous podocyte injuries in the presence of C5b-9 suggests
that triptolide may target downstream molecules of ROS.
ROS may damage cells through direct oxidation of lipids,
proteins and DNA or it can act as a signaling molecule to
trigger intracellular pathways leading to cell injury. In this
study, we evaluated the effect of triptolide on the MAPK-
signaling pathway as the downstream targets of cellular
ROS. There are at least three MAPK pathways as follows:
ERK-1/2 (p44/p42), c-Jun NH2-terminal kinase (JNK), and
p38 MAPK. All three MAPK pathways may contribute to
ROS-mediated cell injury.34–36 We found that C5b-9 stimu-
lated a strong increase in phosphorylated p38 in podocytes
after 1 h of incubation. In contrast, C5b-9 treatment had no
significant effect on phospho-ERK1/2 and c-jun MAPK. P38
is the major MAP kinase activated by oxidative stress in
several cells under various stimuli. It is believed that activa-
tion of p38 MAPK is related to podocyte injury and
development of proteinuria, as well as actin cytoskeleton
disruption.37 A study by Ren et al.38 has also shown that
C5b-9 assembly leads to glomerular epithelial cell injury via
apoptosis signal-regulating kinase 1 and p38 in glomerular
epithelial cell which overexpressed apoptosis signal-regulat-
ing kinase 1. In our study, we showed that p38 MAPK
inhibitor SB-203580 successfully reduced C5b-9-induced
podocyte damage, indicating that p38 MAPK phosphory-
lation mediated C5b-9-induced podocyte injury. In addition,
we found that triptolide significantly inhibit C5b-9-induced
p38 MAPK activation in podocytes. Chen et al.39 showed that
triptolide blocked MAP kinase phosphatase-1 expression.
MAP kinase phosphatase-1s have an important role in the
feedback control of MAP kinase signaling.40 However, the
concentration of triptolide (5 mmol/l) used to suppress MAP
kinase phosphatase-1 expression is much higher than that used
in our study. The mechanism by which triptolide regulate
C5b-9-induced p38 MAPK activity needs further study.
Small GTPase-Rho-mediated signal transduction is a
ubiquitous pathway in various kinds of cells. It is a direct
upstream signaling that controls actin filament reorganiza-
tion, directing cellular behaviors and phenotypic alterations.
RhoA also has an important role in podocyte cytoskeleton
organization.41 Proper regulation of Rho GTPase is required
for maintaining differentiation of podocytes.42 We hypo-
thesized that RhoA might also contribute to the protective
effects of triptolide against C5b-9-induced lesions. We found
that triptolide pretreatment restored RhoA activity, which
was suppressed in C5b-9-treated podocytes. In addition, C3
exoenzyme, a highly selective inhibitor of RhoA, abolished
the effect of triptolide, as shown by western blotting
and immunofluorescence staining. These findings strongly
suggested that restoration of RhoA activity mediated the
protective effect of triptolide.
Complement regulatory proteins, such as CD59, inhibits
assembly of complete large membrane attack complex within
the membrane of a cell under attack.43 However, unlike
complement regulatory proteins, triptolide did not affect
C5b-9 assembly, as shown by indirect immunofluorescence
and confocal microscopy, as well as flow cytometry using
antibody targeting poly-C9 component.
In summary, triptolide can effectively reduce proteinuria
and inhibit immune-mediated injuries in PHN. This
antiproteinuric effect accompanied with recovery of podocyte
injuries in this model, including a decrease in desmin
expression, restoration of nephrin redistribution, and foot
process effacement. Multiple signal pathways involved in the
effect of triptolide on podocytes. Both the immunosuppres-
sive effects and podocyte protection contribute to the
therapeutic effect of triptolide in Heymann nephritis.
MATERIALS AND METHODS
Reagents
Triptolide (C20H24O6, molecular weight 360) was obtained from
Chinese National Institute for Control of Pharmaceutical and
Biological Products (Beijing, China). The purity of triptolide was
detected by high-performance liquid chromatography to be 99.99%.
Triptolide was reconstituted in 0.01% dimethyl sulfoxide and freshly
diluted with culture medium before use. Dimethyl sulfoxide’s
concentration in in vitro studies was less than 0.002% (v/v). FK506
was provided by Fujisawa Pharmaceutical Co. and dissolved in
saline. Purified complement components including C5b6, C7, C8
and C9 were purchased from Calbiochem (San Diego, CA, USA).
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Apocynin, 2-thenoyltrifluoroacetone (TTFA), myxothiazol, and
diphenyl iodonium (DPI) were purchased from Sigma (St Louis,
MO, USA).
Induction of passive Heymann nephritits
FxIA tubular antigen was prepared from renal cortices of Wistar rats.
New Zealand white rabbits were immunized with FxIA antigen and
the rabbit antiserum was prepared. Adult female Sprague–Dawley
(SD) rats (Experimental Animal Center, Jinling Hospital, Nanjing)
with body weights of 150 to 180 grams were given two intraperitoneal
injections of anti-Fx1A antiserum, 2 and 1ml sequentially with 1 hour
intermission. 24-h urine collections were done on individual rats in
metabolic cages. Protein content was determined by the Bradford
method. Urine creatinine was detected by enzymatic method with kits
(Randox, Crumlin, County Antrim, North Ireland). Treatment with
triptolide started 10 days after antiserum injection when proteinuria
was already present.
Rats with passive Heymann nephritis (n¼ 32) were orally
administered triptolide (200 mg/kg/d). For the pretreatment group,
rats (n¼ 6) were pretreated with triptolide (200 mg/kg/d) 2 days
before the induction of PHN and continued throughout the
experiment. In the treatment group with FK506, rats (n¼ 6) were
orally administered 1mg/kg of FK506. As controls, another 32 rats
with passive Heymann nephritis were given an oral dose of 1ml
normal saline solution containing 0.4% dimethyl sulfoxide every
day. 10 healthy rats were chosen as normal controls.
Schedule of laboratory tests and sample collection
Rats were housed under standard conditions (air-conditioned room,
221C) with free access to food and water. After proteinuria was
established in PHN rats, treatment with triptolide started on day 1
and continued until day 28. Once a week, 24-h urine samples were
collected after the rats had been transferred to metabolic cages with
free access to water but without food. After treatment with triptolide
for 7, 14, 21 and 28 days, blood samples were taken from the retro
bulbar plexus of the ketamine-anesthetized rats, eight rats in each
group were killed after ketamine narcosis. Blood and urine samples
were immediately subjected to standard laboratory tests to measure
serum levels of albumin, aminotransferases, creatinine, and white
blood cell count. Renal tissues were processed for morphological
studies and immunofluorescence microscopy.
Assay of circulating rat antibodies against rabbit
The amount of circulating antibodies to rabbit IgG was determined
using ELISA. Plates (Organon Teknika, Ireland) were coated with
4.0mg/ml rabbit IgG in 0.1 M sodium carbonate buffer (pH 9.6) and
incubated for 20 h at 41C. After blocking with 1% BSA and then
washing the plates with PBST (10mM PBS, pH 7.4, 0.2% Tween 20),
rat serum of PHN rats with or without treatment with triptolide
were added and incubated for 1 hour at 371C. After washing with
PBST, Horseradish peroxidase (HRP) labeled sheep polyclonal
antibody against rat (1:2000, Southern Biotechnology Associates,
Birmingham, AL, USA) was applied and incubated for 1 hour. After
washing, o-phenylenediamine and H2O2 were added. The reaction
was terminated by 1M H2SO4. The absorbance was measured
chromatically at 492 nm with an ELISA-reader (Thermo Multiskan
Spectrum, Waltham, MA, USA).
Morphological studies by light microscopy
Kidney tissues were fixed in 10% formalin, dehydrated in graded
alcohol and embedded in paraffin. 2 mm sections were cut and
stained with hematoxylin and eosin, periodic acid-Schiff regent,
periodic acid-sliver methenamine and Masson’s trichrome. All slides
were evaluated by the same pathologist who was unaware of the
nature of the experimental groups at Nikon E800 microscope.
Morphological studies by transmission electron microscopy
Blocks of renal cortex tissue (lmm3) were fixed in cold 3.75%
glutaraldehyde for 4 h. After washing in 0.1 M phosphate buffer (pH
7.5) for 5–6 times, renal tissue was post fixed in 2% osmium
tetroxide for 2 h, dehydrated in graded acetone and ethanol, and
embedded in epoxy resin (SPI, Indianapolis, IN, USA). Ultra thin
sections (80–90 nm) were stained with uranyl acetate and lead
citrate, then examined and photographed in a Hitachi 7500
transmission electron microscope (Hitachi, Tokyo, Japan).
For evaluation of the foot process width per length of GBM,
images covering one glomerular cross-section were obtained in
electron microscope. With the use of SimplePCI software (Compix,
Irvine, CA, USA), the length of the peripheral GBM was measured
and the number of foot process overlying this GBM length was
counted. The arithmetic mean of the foot process width was
calculated as : (p/4) (PGBM length/Pnumber of foot process),44
where
P
GBM length is the total GBM length measured in one
glomerulus,
P
number of foot process is the total number of foot
process counted. The correction factor p/4 serves to correct the
random orientation in which the foot processes are sectioned.
For semiquantification of the subepithelial immune deposits, all
exposure settings were kept constant for each group of kidneys.
Subepithelial dense deposits around each capillary were outlined
and the gray value of subepithelial immune deposits was read from
the Histogram command in Adobe Photoshop.24
Immunofluorescence and immunohistochemistry
Renal cortex was embedded in Tissue-Tek OCT Compound, snap-
frozen in liquid nitrogen and cut in a cryostat (Leica CM 3050S,
Nussloch, Germany).
To observe the deposition of IgG and C5b-9 in glomeruli, 4mm
cryosections were fixed in acetone, washed with cold PBS, blocked
with 1% bovine serum albumin in PBS, and stained with fluorescein
isothiocyanate (FITC)-conjugated goat anti-rat IgG(1:100, Chemi-
con, Billerica, MA, USA), mouse anti-rat C5b-9(1:100, DAKO,
Carpinteria, CA, USA), which was followed by FITC-conjugated
goat anti-mouse IgG(1:50, DAKO).
To observe the expression and distribution of nephrin, the
sections were stained with mouse anti-rat nephrin, mAb 5-1-6
(1:400, a gift from professor Hiroshi Kawachi in Niigata University,
Japan), followed by FITC-conjugated goat anti-mouse IgG(1:50,
DAKO). All the sections were examined by immunofluorescence
microscope (Nikon Eclipse E800, Tokyo, Japan). All exposure
settings were kept constant for each section.
The sections were examined by epifluorescent microscopy that
used a Nikon Pan Fluor lens. The images were captured with a Spot
CCD camera and exported into Adobe Photoshop. All exposure
settings were kept constant for each group of kidneys. Fluorescence
intensity was measured by outlining the perimeter of six glomeruli
in each section and reading the luminosity from the Histogram
command in Adobe Photoshop.44 Calibration of the CCD exposure
time assured that the settings chosen were in the linear range and
well below saturation.
For immunohistochemical analysis of desmin expression,
sections were incubated with mouse monoclonal antibody against
rat desmin (D33, DAKO) for 1 h. Then the sections were incubated
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with HRP-conjugated secondary antibody (Envision kit, DAKO) for
40min. Color was developed by incubation with AEC (DAKO) and
the sections were counterstained with hematoxyline. All the sections
were examined by a microscope (Nikon E800) and all exposure
settings were kept constant for each section.
Mouse podocyte culture
Conditionally immortalized mouse podocytes were a kind gift
from Professor Stuart J Shankland (University of Washington,
Seattle, WA, USA). Podocytes were cultured in RPMI-1640 medium
containing 10% fetal bovine serum, 100U/ml penicillin, and
100mg/ml streptomycin (Gibco-BRL, Gaithersburg, MD, USA).
Podocytes were expanded by culture in a medium containing
10U/ml mouse interferon-g (R&D Systems, Minneapolis, MN,
USA) at 331C. Removal of interferon-g and switching growth
temperature to 371C for 10–14 days caused podocytes to stop
proliferating and undertake a differentiated phenotype.45 Podocytes
were starved from FCS for 24 h before all experiments.
Assembly of C5b-9 membrane attack complex on podocytes
in vitro
Purified human complement components C5b-6 to C9 were used to
assemble C5b-9. The capacity of this complex to lyse chicken
erythrocytes was confirmed before use. Differentiated podocytes
were washed three times with serum-free medium. Assembly of
intact C5b-9 was initiated by a 15min pre-incubation (371C) with
C5b-6 (0.8 mg/ml) and C7 (10 mg/ml), then complement component
C8 and C9 (10 mg/ml each) were added, and cells were incubated
for an additional 30min.46 Podocytes were washed with serum-free
medium to remove excess non-complex complement components
and incubated with serum-free medium for indicated time.
Alterations of membrane integrity because of the formation of
C5b-9 complex were determined by measuring the release of enzyme
lactate dehydrogenase (LDH) using a kit purchased from Roche
(No. 1644793; Grenzach-Wyhlen, Germany). The formation of
C5b-9 on the membrane of podocytes were verified by confocal
microscopy (LSM 510, Carl Zeiss, Jena, Germany) and flow
cytometry (FACS Aria, Becton Dickinson, San Jose, CA, USA)
using antibody to C5b-9 (DAKO). In experiment with triptolide
acting on C5b-9 assembly, podocytes were pretreated with triptolide
(10 ng/ml) for 30min before adding C5b-9.
Actin cytoskeleton staining and p47phox immunostaining
Cells were fixed with 4% paraformaldehyde, incubated with 0.5%
Triton X-100 for 10min, and stained with 0.5 ng/ml Rhodamin–-
phalloidin (Cytoskeleton, Denver, CO, USA) for 40min in darkness.
Subcellular localization of the p47phox subunits of NADPH oxidase
was evaluated in podocytes fixed with 4% paraformaldehyde for
20min on ice. After preincubation in blocking buffer, the cells were
incubated with a 1:50 dilution of goat anti-p47phox (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). After washing, the cells
were incubated with 1:50 dilutions of FITC-conjugated donkey
anti-goat IgG (Santa Cruz). Negative controls were prepared by
omitting the primary antibodies. Cover glasses were mounted, and
the slides were examined by immunofluorescence microscope
(Nikon Eclipse E800).
Reactive oxygen species (ROS) assay
The intracellular production of ROS was assayed using the
fluoroprobe CM-H2DCFDA (chloromethyl-2, 7-dichlorodihydro-
fluorescein diacetate, Molecular Probes, Eugene, OR, USA). To
examine the effect of C5b-9 on ROS generation by podocytes,
podocytes were stimulated with C5b-9 for 10, 30, 60 and 90min.
To determine the effect of triptolide on C5b-9-stimulated ROS
generation, podocytes were treated with triptolide (10 ng/ml) before
or after C5b-9 has been assembled for 30min, After the treatment,
cells were loaded with 10 ı`mol/l CM-H2DCFDA. Cells were
immediately analyzed using flow cytometry. For each sample,
10,000 events were collected and the content of ROS was assessed
by mean fluorescence intensity (MFI).
Western blot analysis of MAPK activation
Glomeruli of experimental rats were isolated by the standard sieving
method. The glomeruli or cultured podocytes were rinsed with ice
cold PBS with sodium orthovanadate and lysed with lysis buffer
(50mM Tris, 150mM NaCl, 10mM ethylenediaminetetraacetic acid,
1% Triton X-100) containing protease and phosphatase inhibitors
on ice. The lysates (50 mg) were heated for 5min at 951C in sample
buffer, separated on 10% polyacrylamide sodium dodecyl sulfate
gel and transferred onto PVDF membrane. Membranes were blocked
for 1 h at room temperature with 5% powdered milk in Tris-HCl
buffer containing Tween 20 (TTBS). Primary antibodies were diluted
in TTBS and added as follows: anti JNK and anti-phospho-JNK,
anti ERK 1/2, anti-phospho-ERK1/2, anti p38, antiphospho-p38 and
anti GAPDH (Santa Cruz Biotechnology; mouse monoclonal IgG,
dilution 1:200); anti GAPDH (Sigma-Aldrich; mouse monoclonal,
dilution 1:10,000). The membranes were incubated with primary
antibodies overnight at 41C followed by incubation with secondary
antibodies (donkey anti-mouse IgG HRP-conjugated, Jackson
ImmunoResearch Laboratories, West Grove, PA, USA; dilution
1:10,000) at room temperature for 1 h. Blots were detected using an
enhanced chemiluminescence detection system (Millipore Corporation,
Billerica, MA, USA) according to the manufacturer’s instructions.
Exposures were recorded on Hyper-film (Amersham Bioscience UK Ltd,
Buckinghamshire, England) for different time points and quantified by
use of a densitometer (Bio-Rad Laboratories, Munich, Germany).
RhoA activation assay by pull-down experiment
RhoA activation was studied using the RhoA activation kit
(Cytoskeleton) according to the manufacturer’s recommendations.
After cell lysis, about 300mg of protein was incubated with 50mg of
Rhotekin-RBD protein beads (GST fusion protein containing the
RhoA-binding domain of Rhotekin). The bound proteins were
fractionated on 12% SDS-polyacrylamide gel electrophoresis and
immunoblotted with anti-RhoA monoclonal antibody. The level of
active RhoAwas determined after normalization with the total RhoA
presented in the cell lysates.
Statistical analysis
Statistical analyses were performed with SPSS software (version
11.5). Results were expressed as mean±s.d. Student’s t-test was used
to compare differences between groups. Po0.05 was considered
statistically significant, and Po0.01 was considered highly statisti-
cally significant.
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